Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma

This article was published in the following Dove Press journal:
International Journal of Nanomedicine
4 December 2014
Number of times this article has been viewed

Abstract: Liposomes constitute one of the most popular nanocarriers for improving the delivery and efficacy of agents in cancer patients. The purpose of this study was to design and evaluate immunoliposome co-delivery of bufalin and anti-CD40 to induce synergetic therapeutic efficacy while eliminating systemic side effects. Bufalin liposomes (BFL) conjugated with anti-CD40 antibody (anti-CD40-BFL) showed enhanced cytotoxicity compared with bufalin alone. In a mouse B16 melanoma model, intravenous injection of anti-CD40-BFL achieved smaller tumor volume than did treatment with BFL (average: 117 mm³ versus 270 mm³, respectively); the enhanced therapeutic efficacy through a caspase-dependent pathway induced apoptosis, which was confirmed using terminal deoxynucleotidyl transferase-mediated dUTP-Fluorescein nick end labeling and Western blot assay. Meanwhile, anti-CD40-BFL elicited unapparent body-weight changes and a significant reduction in serum levels of tumor necrosis factor-α, interleukin-1β, interleukin-6, interferon-γ, and hepatic enzyme alanine transaminase, suggesting minimized systemic side effects. This may be attributed to the mechanism by which liposomes are retained within the tumor site for an extended period of time, which is supported by the following biodistribution and flow cytometric analyses. Taken together, the results demonstrated a highly promising strategy for liposomal vehicle transport of anti-CD40 plus bufalin that can be used to enhance antitumor effects via synergetic systemic immunity while blocking systemic toxicity.

Keywords: liposomes, bufalin, anti-CD40, chemoimmunotherapy

Introduction

Bufalin, one of the major digoxin-like components, is extracted from the skin and parotid venom glands of the toad Bufo bufo gargarizans cantor or Bufo melanostictus.Bufalin has excellent antitumor effects against various solid tumors, including those associated with leukemia, osteosarcoma, gastric cancer, prostate cancer, ovarian cancer, and colon cancer. Previous studies have suggested that the anticancer activity of bufalin could be attributed to its well-documented inhibition of cell proliferation, induction of apoptosis, disruption of the cell cycle, and regulation of the immune response. Although these results are promising, the use of this single chemotherapeutic drug is far from perfected and is associated with undesirable severe side effects such as immunosuppression, damage to normal tissues, high toxicity, and development of drug resistance.

Tumors are known to elicit tolerated immune responses against tumor-associated self-antigens while simultaneously inducing local immune suppression as a mechanism to avoid detection and elimination by the host immune system itself. To some extent, these effects can be complemented and counterbalanced by immunotherapy. The overall goal of immunotherapy is the induction and amplification of functional antitumor response.
antigen-specific immune responses for the development of long-lasting immunological memory to treat cancer. Immunotherapy is a novel treatment modality that kills tumor cells via induction of effective humoral immune responses. Intermediates of melanogenesis, which are simultaneously released by melanocytes, may even affect the immune system, and the response rates and low toxicities reported in malignant melanoma suggest that antigen-based active immunotherapy may complement current treatment, even though no relevant cancer vaccines for melanoma have been approved by the US Food and Drug Administration (FDA).15–17 The major challenge to be solved is how to prevent melanoma from establishing neuroendocrine axes and rewiring the local and systemic homeostatic responses, in turn securing tumor survival and growth to the detriment of the host during stage 3 (regional metastasis) and stage 4 (distant metastasis) disease.18 For this reason, immunotherapy is emerging as a therapy in which the ability of the systemic immune system is exploited. The key to successful synergy therapy is to design a simple, novel co-delivery system that combines chemotherapy with immunotherapy in order to treat cancer patients while keeping side effects to a minimum.19

The various forms of combined immunotherapy include monoclonal antibodies (mAbs), adoptive lymphocyte transfer, and active specific immunotherapy, with monoclonal antibody therapy as the most common.20,21 CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily and is expressed on the surface of a variety of noncancer cells, such as B cells, macrophages, dendritic cells (DCs), myeloid cells, epithelial cells, and endothelial cells.22,23 The CD40–CD40 ligand interaction provides a costimulatory signal to antigen-presenting cells (APCs), thereby augmenting the capability of APCs to present antigens and stimulating the production of proinflammatory cytokines and delivery-positive costimulatory signals, which in turn promotes antitumor cytotoxic T-cell responses. Qu et al24 demonstrated that chemotherapy regimens with gemcitabine or 5-fluorouracil enhance the antitumor effect of anti-CD40 in the mouse B16 melanoma model. However, intravenous infusion of anti-CD40 mAbs results in inflammatory effects, such as symptoms of cytokine-release syndrome and liver damage due to systemic exposure.25

In light of the dangers of the potential systemic side effects, incorporating both a chemotherapeutic agent and monoclonal antibody delivery into the tumor sites simultaneously has been proposed to achieve a synergy for cancer therapies. Among several nanocarriers, including micelles, liposomes, and inorganic nanoparticles, liposomes have been extensively studied and are FDA-approved as a safe material for drug-delivery applications due to their enhanced permeability and retention mechanism (EPR effects).26 Until now, most investigations demonstrated that liposomes are able to retain the bioactivity of therapeutics within local tumor tissues as well as improve the solubility of chemotherapy drugs. Li et al27 prepared bufadienolides-loaded nanostructured lipid carriers, which showed an improved pharmacokinetic profile and reduced distribution in heart tissue. In this regard, polyethylene glycol (PEG) inserted into liposomes (PEGylated liposomes) are ideally suited because of their well-established versatile platform for exploring multiple approaches that not only potentially improved the delivery but also enhanced the local retention of therapies to the tumor itself.

In the present study, we employed a liposome co-delivery system that coupled anti-CD40 mAbs to the surface of PEGylated unilamellar liposomes wrapped with bufalin. This vector has shown a dual advantage of retaining the cytotoxic behavior of bufalin while expressing the immune response of anti-CD40. The combination chemoimmunotherapy of anti-CD40 plus bufalin by liposomal carriers was exploited to enhance anticancer therapeutic efficacy while reducing systemic toxicity, due to the confined biodistribution and prolonged release of cargo.

Materials and methods
Chemicals and reagents
L-α-phosphatidylcholine (EPC), cholesterol, dithiothreitol (DTT), and Tween 20 were purchased from Sigma-Aldrich (St Louis, MO, USA). 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000] (DSPE-PEG<sub>2000</sub>-Mal), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (ammonium salt; DSPE-PEG<sub>2000</sub>), and rhodamine-phosphoethanolamine (Rho-PE) were obtained from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Bufalin (purity &gt;98%) was purchased from BaoJi Chen-Guang Technology Development Co. Ltd (Baoji, Shaanxi, People’s Republic of China). Monoclonal anti-CD40 (clone FGK4.5, rat IgG2a) was purchased from Bio X Cell (West Lebanon, NH, USA). Zeba desalting columns were obtained from Pierce (Thermo Fisher Scientific, Rockford, IL, USA). Secondary antirat IgG was purchased from Jackson ImmunoResearch Labs (West Grove, PA, USA). Anti-CD40 enzyme-linked immunosorbent assay (ELISA) kits were purchased from Blue Gene Technology Development Co. Ltd (Shanghai, People’s Republic of China). Antimouse CD45

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 54.70.40.11 on 26-Feb-2019
For personal use only.
(clone 30-F11), antimouse CD4, antimouse CD3, antimouse CD8a, and antimouse CD11c (N418) were obtained from Biolegend (San Diego, CA, USA). Cytochrome c and caspase-9 were obtained from Santa Cruz Biotechnology Co., Ltd (Dallas, TX, USA), and caspase-3 was obtained from ABclonal Biotech Co., Ltd (Cambridge, MA, USA).

**Animals and cells**

The animal experiments were conducted according to the Guidelines for Animal Experimentation of the Fourth Military Medical University (FMMU), Xi’an, People’s Republic of China. The study protocol was approved by ethical committees of FMMU. C57/BL6 female mice were obtained from the Experimental Animal Center of FMMU at 6–8 weeks of age (initially weighing 20±2 g). Animal procedures were performed in accordance with the FMMU Institutional Authority for Laboratory Animal Care.

B16 melanoma cells (American Type Culture Collection CRL-6475™) were purchased from the FMMU Experimental Animal Center, cultured in Roswell Park Memorial Institute 1640 medium supplemented with 10% (v/v) fetal bovine serum and 1% antibiotics (100 U/mL penicillin G and 0.1 mg/mL streptomycin). Cells were maintained in their exponential growth phase in an atmosphere of 5% CO₂ and 90% relative humidity at 37°C.

**Synthesis of bufalin liposome-anchored anti-CD40**

Liposomes were prepared by thin lipid film hydration followed by sonication and extrusion as reported by Iyer et al. In brief, liposomes were synthesized with a composition of cholesterol, EPC, DSPE-PEG<sub>2000</sub>, DSPE-PEG<sub>2000</sub>-Mal, and bufalin in a molar ratio of 20:55:5:5:15, respectively. Different ratios of phospholipid mixtures in chloroform were evaporated by a rotary evaporator at 35°C for 1 hour. The thin lipid layer was subsequently dried in a vacuum desiccator overnight to remove residual solvent (if any), and then the prepared dry thin film was rehydrated in phosphate-buffered saline (PBS) at 10 mmol/mL phospholipid at 60°C for 30 minutes to form maleimide-functionalized bufalin liposomes.

For preparation of bufalin liposome-anchored anti-CD40, anti-CD40 monoclonal antibody was conjugated to maleimide-functionalized liposomes through the maleimide–thiol reaction. In brief, anti-CD40 was mixed with excess DTT in the presence of 10 mM ethylene diamine tetraacetic acid (EDTA) in PBS for 20 minutes at 25°C and passed through a desalting column to remove unreacted DTT. The exposed sulhydryl residues on the antibody were conjugated to maleimide-functionalized liposomes at a ratio of 1 mg antibody to 2 mmol liposomes for at least 10 hours at 25°C in the presence of 10 mM EDTA.

The resulting liposome suspension was immediately extruded with a LipoFast-Pneumatic Lipex extruder (Avestin; Ottawa, ON, Canada) five times using polycarbonate membranes (0.2 µm pore size; Whatman; Maidstone, UK) to form unilamellar liposomes, and then centrifuged and washed multiple times with PBS to remove unbound antibody and bufalin.

**Characterization of liposomes**

**Particle size, zeta potential, and morphology of liposomes**

The particle size distribution and zeta potential of liposomes were determined by dynamic light scattering technique using the Delta™ Nano zeta potential analyzer (Beckman Coulter, Brea, CA, USA). Morphological evaluation of the liposomes was observed by a transmission electron microscope (TEM; Hitachi H-7650; Tokyo, Japan). For TEM studies, samples were placed over a copper grid and samples were negatively stained with 1% phosphotungstic acid.

**Percentage entrapment of drugs in the liposomes**

Percentage drug encapsulation in the liposomes was determined by centrifugation. The liposomes were centrifuged at 14,000 rpm for 20 minutes to remove the unloaded drug and then mixed with 10x volume of methanol to solubilize the lipids. The bufalin concentration was measured by high-performance liquid chromatography (HPLC). The entrapment efficiency of bufalin in the liposomes was estimated as:

\[ E = \left( \frac{W_{\text{encapsulated}}}{W_{\text{total}}} \right) \times 100\% \]

where E is the encapsulation efficiency of liposomes, \( W_{\text{encapsulated}} \) is the measured amount of bufalin in the liposome suspensions after centrifugation, and \( W_{\text{total}} \) is the measured amount of bufalin in the equal volume of liposome suspensions before centrifugation.

Bufalin was quantified by an Ximate C18 column (250×4.6 mm, 5 µm) (Welch Materials, Inc., Shanghai, People’s Republic of China) and detected by HPLC with a photodiode array detector method. The mobile phase was composed of 1) 0.5% monopotassium phosphate (adjusted to pH 3.2 using phosphoric acid) and 2) acetonitrile, using a gradient elution and performed at 40°C with a flow rate of 1.0 mL/minute.
In vitro release of bufalin and anti-CD40 from liposomes

The in vitro release behaviors of bufalin and anti-CD40 mAbs from the liposomes were investigated using dialysis. Briefly, 1 mL of liposomal solution was dialyzed against 20 mL PBS (pH 7.4) containing 10% fetal calf serum in a dialysis tube (molecular weight cutoff = 30 kDa) with gentle horizontal shaking (120 rpm). The dialysate was withdrawn from the medium and replaced with an equal volume of fresh PBS at the predetermined time points. The concentration of bufalin was measured by HPLC, and anti-CD40 was measured by ELISA according to the manufacturer’s protocol.

In vitro cell cytotoxicity

In vitro cytotoxicity was evaluated using the cholecystokinin (CCK)-8 assay (Beyotime Institute of Biotechnology, Shanghai, People’s Republic of China). B16 cells were seeded in 96-well microtiter plates at a density of 5×10^4 cells per well and incubated (37°C, 5% CO2) for 24 hours. Anti-CD40 solution, free bufalin, BFL, and anti-CD40-BFL were added to cells in a total final volume of 100 µL per well for 6 hours and 24 hours. The BFL and anti-CD40-BFL with bufalin concentrations of 500 µmol/L were prepared, and diluted into bufalin concentrations of 300 µmol/L, 250 µmol/L, 200 µmol/L, 150 µmol/L, 100 µmol/L, and 50 µmol/L consecutively. The concentrations of free antibody were identical to the concentrations of the antibody conjugated to liposomes, and the blank liposomes were evaluated to test the toxicity of the nanocarrier. Ten microlitres of CCK-8 assay agents were added to the culture medium at given time intervals, and the cells were incubated for another hour. Absorbance was measured on a microplate reader at 450 nm with a reference wavelength of 690 nm.

In vivo antitumor efficacy

For in vivo tumor experiments, approximately 5×10^4 B16 cells suspended in physiological saline were subcutaneously injected into the hind flank of female C57/BL6 mice on day 0. After the growing tumors were palpated, mice were assigned randomly into five groups (eight mice per group). Tumor sizes were measured by vernier caliper and calculated using the following equation: volume (mm^3) = (major axis × minor axis^2) × 0.5. The antitumor therapy experiments were commenced when tumor size reached 3–5 mm in diameter on day 9. The mice were then treated with tail-vein injections of PBS, bufalin solution, soluble anti-CD40, BFL, or anti-CD40-BFL from day 9–15 every other day. The bufalin dose was 1 mg/kg and the anti-CD40 dose was 8 mg/kg in each pure or liposome solution. Throughout the study, weight and tumor size were monitored daily. Mice were sacrificed when the tumor size in the control group reached 800 mm^3, and every tumor, spleen, and lymph node were harvested. One portion of the harvested tumors was fixed in 10% formalin, processed into paraffin-embedded sections at a thickness of 4 µm, and stained with hematoxylin and eosin for histopathological analysis.

Serum measurements of serum cytokine levels

For the measurement of circulating inflammatory markers, serum samples were taken via retro-orbital bleeding after injection for 24 hours, followed by centrifugation at 5,000 rpm to remove the cellular fraction. Circulating serum levels of TNF-α, interleukin (IL)-1β, IL-6, and interferon (IFN)-γ were quantified by ELISA according to the manufacturer’s protocol. The serum level of free anti-CD40 was measured by ELISA using recombinant CD40 receptor. Levels of the hepatic enzyme alanine transaminase (ALT) were measured using a standard biochemical assay (Infinity ALT reagent kit; Thermo Fisher Scientific).

Apoptosis assay

Tumors were isolated and immediately snap-frozen and sliced at a thickness of 10 µm during cryosectioning. The cryosections were mounted onto Superfrost Plus glass slides (Fisher Scientific; Houston, TX, USA) and fixed with acetone. The cell apoptosis of tumors was confirmed by in situ fluorescent terminal deoxynucleotidyl transferase-mediated dUTP-Fluorescein nick end labeling (TUNEL) staining, according to the manufacturer’s protocol (Roche, Basel, Switzerland). Briefly, the cryosections were fixed by 4% paraformaldehyde in PBS for 20 minutes and then permeabilized on ice and incubated with the TUNEL reaction mixture at 37°C for 1 hour. The fluorescein labels incorporated into the damaged sites of the DNA were detected by fluorescent microscopy. Subsequently, the slides were treated with 50 µL 4,6-diamidino-2-phenylindole solution (5 µg/mL) for 10 minutes to stain the nuclei, washed thrice, and covered by antifade mounting medium. Images were taken under a FluoView FV1000 confocal microscope (Olympus, Tokyo, Japan).

Western blot analysis

Frozen tissue samples (∼100 mg) were quickly homogenized in lysis buffer (1% Triton ×100, 50 mM Tris HCl, 150 mM

beta
NaCl containing protease inhibitors. After 30 minutes incubation on ice, samples were centrifuged for 30 minutes at 4°C at 14,000 rpm. The supernatants were assayed for protein levels according to the Bradford method with bovine serum albumin as the standard. Aliquots of 50 µg of protein in each sample were denatured at 90°C for 5 minutes, resolved by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and then transferred onto a polyvinylidene difluoride membrane. The blotted membrane was blocked with 5% nonfat milk in PBS pH 7.4 plus Tween 20 and incubated with the respective primary antibodies (cytochrome c, caspase-3, caspase-9, or β-actin as a standard) at 4°C overnight, washed, and then incubated with the corresponding horseradish peroxidase-conjugated antimouse secondary antibody for 2 hours. After several washes, the immunoreactions were visualized by an enhanced chemiluminescent detection kit (GE Healthcare Life Sciences, Piscataway, NJ, USA) and exposed to X-ray film. Films of Western blots were scanned and quantified using an image processor.

**Results**

### Synthesis and characterization of anti-CD40-BFL

Liposomes combined with anti-CD40 mAbs restricted the dissemination of conjugated ligands and resulted in subdued systemic toxicity and side effects. mAbs binding to the maleimide-functionalized liposomes containing the mixture of cholesterol, EPC, DSPE-PEG<sub>2000</sub>, DSPE-PEG<sub>2000</sub>-Mal, and bufalin (20:55:5:15 molar ratio) is illustrated as a schematic in Figure 1A. The disulfides in the hinge region of the antibody mildly reacted with maleimide, and the amount of mAbs conjugated was only closely related to the quantity of maleimide–PEG–lipid and weakly influenced because the vesicle composition was settled. To evaluate the efficiency of our synthesis, the concentration of anti-CD40 was measured by ELISA analysis of liposomes lysed by Tween 20 surfactant, and anti-CD40 density on the liposomes was estimated to be 5 mg/mL.

The particle size distribution and zeta potential of liposomes, measured by dynamic light scattering, are summarized in Figure 1B. Anti-CD40-BFL had a mean particle size of approximately 205.4±68.4 nm with a narrow range of size distribution (polydispersion index =0.062), while the mean particle size of BFL was 171.4±69.2 nm (polydispersion index =0.088). All liposome formulations exhibited a similar negative surface charge, suggesting excellent stability (anti-CD40-BFL: −15.68 mV; BFL: −30.71 mV; Table S1). The surface morphology determined by TEM revealed a uniform spherical shape, and the sizes were smaller than those from dynamic light scattering due to the presence of hydrated layers around the particle surfaces (Figure 1C). However, the drug encapsulation efficiency of BFL and anti-CD40-BFL as determined by HPLC were 87.85%±4.23% and 73.59%±3.14%, respectively. Anti-CD40-BFL had a lower drug encapsulation efficiency, which was mainly due to the prolonged time it was stirred.

The cumulative drug release profiles of bufalin and anti-CD40 from liposomes in vitro indicated that free bufalin and anti-CD40 could be nearly 80% from solution within 4 hours, suggesting it diffused through the dialysis membrane freely (Figure 2). By contrast, the liposomes had a substantially good shelf life. As for anti-CD40-BFL, the initial release of bufalin began at 6 hours, indicating that bufalin was steadily diffused through the dialysis membrane freely (Figure 2). By contrast, the liposomes had a substantially good shelf life. As for anti-CD40-BFL, the initial release of bufalin began at 6 hours, indicating that bufalin was steadily diffused through the dialysis membrane freely (Figure 2). By contrast, the liposomes had a substantially good shelf life.
Figure 1 Preparation schematic and characterization of PEGylated liposomes containing bufalin with or without anti-CD40.

Notes: (A) Schematic illustration of the surface coupling of anti-CD40 to PEGylated liposomes via maleimide–thiol reaction. (B) Particle size distribution of BFL and conjugated with anti-CD40 antibody (anti-CD40-BFL) in the range of 150–200 nm, as measured by dynamic light scattering. (C) TEM images of BFL and anti-CD40-BFL, with a uniform spherical shape.

Abbreviations: BFL, bufalin liposomes; DTT, dithiothreitol; Mal-thiol, maleimide–thiol; SH, sulphydryl; TEM, transmission electron microscope.
incorporated into the lipid bilayer due to its semblable structure of cholesterol and no evidence of drug burst release. Approximately 90% of bufalin was released within 72 hours, while anti-CD40 was close to 50%. The release profiles obtained from both bufalin and anti-CD40 indicated that the co-delivery system provided a possibly synergistic effect.

**In vitro cytotoxicity**

The CCK-8 assay was carried out to determine the cell viability (Figure 3). Bufalin caused a dramatic inhibition of growth in B16 cells in a dose-dependent manner, while changes in cell viability of blank liposomes did not indicate any changes in cell viability. Cell viability was <50% after treatment with 300 nmol/L of free bufalin for 6 hours, which was significantly higher than that of liposomes, dominantly attributed to the controlled release of liposome. After 24 hours, the cell viability of bufalin was adverse, while BFL exhibited remarkable cytotoxicity on B16 cells, explained by the fact that cells could efficiently uptake liposomes through endocytosis, consistent with IC_{50} (median inhibition concentration).
concentration) results (Table S2; other data not shown). However, the growth inhibitory effect between BFL and anti-CD40-BFL was similar, which can possibly be attributed to the anti-CD40 solution having little effect on cell viability, as previously observed by Kwong et al\textsuperscript{25} due to the absence of CD40 surface expression on B16 cells.

**In vivo therapeutic efficacy**

We evaluated the therapeutic efficacy in C57/BL6 mice bearing B16 cell subcutaneous tumors. After the tumors were palpated (40 mm\textsuperscript{3}), physiological saline was administered via tail-vein injection into mice in the control group. Bufalin solution, anti-CD40 solution, BFL, and anti-CD40-BFL at an equivalent dosage of 1 mg/kg bufalin or 8 mg/kg anti-CD40 antibody per injection were administered by tail-vein injection in the treatment groups every other day, five times.\textsuperscript{30} As illustrated in Figures 4A and C, tumor growth was significantly inhibited in all treatment groups compared with the control group (physiological saline). Anti-CD40-BFL showed greater tumor growth inhibition than bufalin solution alone, which is consistent with the cytotoxic effects observed in vitro, resulting in average tumor volumes of 176.34±43.86 mm\textsuperscript{3} versus 284.35±84.05 mm\textsuperscript{3}, respectively (\(P=0.0341\)). Therapeutic efficacy was enhanced obviously between anti-CD40-BFL and BFL (average tumor volumes of 176.34±43.86 mm\textsuperscript{3} versus 254.53±44.99 mm\textsuperscript{3}, \(P=0.0482\)), as the activated immune response pathways of anti-CD40 could overcome the immunosuppression present in advanced tumors and induce cytotoxic T lymphocyte responses. Nonetheless, the anti-CD40 solution group (average tumor volumes of 477.96±76.89 mm\textsuperscript{3}, \(P=0.0041\)) showed a limited therapeutic effect relative to anti-CD40-BFL, which can be attributed to the potent anticancer effect of bufalin. In addition, the average tumor weight in the physiological saline,

---

**Figure 4** Therapeutic efficacy on C57/BL6 mice carrying subcutaneous B16 melanoma tumors.

**Notes:** (A) Average tumor growth curves from a representative experiment. Mice were given tail-vein injections on day 9, day 11, day 13, and day 15 following tumor cell inoculation with phosphate-buffered saline, soluble anti-CD40, bufalin, BFL, or anti-CD40-BFL at an equivalent dose of 1 mg/kg or 8 mg/kg of anti-CD40 per injection. (B) Body-weight changes of the mice over the experimental period. (C) Photographs of melanoma tumors in each group. (D) Average tumor weight at the endpoint of study. \(P\)-values were determined by paired Student’s \(t\)-tests: *\(P<0.05\), **\(P<0.01\) (\(n=6\), mean ± standard error).

**Abbreviation:** BFL, bufalin liposomes.
bufalin solution, anti-CD40 solution, BFL, and anti-CD40-BFL groups at the end of the experiment were 2.68 g, 1.97 g, 1.15 g, 0.93 g, and 0.55 g, respectively (Figure 4D), and the anti-CD40-BFL group had the lowest tumor weight among all the treatment groups (P=0.0303).

Average body weight changes were observed in order to estimate systemic toxicity (Figure 4B). The anti-CD40 group experienced substantial weight loss relative to the PBS control group, with a weight loss peak of about 8% after two injections. This could be attributed to the ability of anti-CD40 to enter into systemic circulation rapidly after injection to cause widespread inflammatory effects. To the contrary, the body-weight loss in the anti-CD40-BFL group was minimal, since the liposome-based antigen delivery system could provide prolonged and simultaneous delivery of antigen.

**Liposome-triggered tumor cell apoptosis**

Apoptotic signaling cascades result in single-stranded and double-stranded DNA fragmentation and can be detected by TUNEL assay using an in situ cell death detection kit. As shown in Figures 5A and C, the cytosections of the control group had no visible green fluorescence, suggesting the absence of cell apoptosis, while the mild fluorescence in the soluble anti-CD40 and bufalin groups demonstrated partial apoptosis of B16 cells. In contrast, anti-CD40-BFL exhibited stronger fluorescence in most of the cells, indicating an increase in apoptosis in vivo. In addition, hematoxylin and eosin histological analysis of paraffin sections confirmed apoptosis (Figure 5B).

In vivo apoptosis results were verified by Western blot analysis. To determine whether apoptosis is mediated via the activation of caspase-3, caspase-9, and cytochrome c, tumors were harvested and apoptosis-associated protein levels were quantified. As shown in Figure 5D, the integral optical density of anti-CD40-BFL was strongest in caspase-3 (0.92±0.026), caspase-9 (1.58±0.013), and cytochrome c (1.069±0.016), suggesting that anti-CD40-BFL elicits the most powerful apoptosis effect compared with other treatment groups, via a mitochondria-dependent pathway.

**Serum cytokine levels**

Serum cytokine levels administered 24 hours posttreatment were measured to evaluate systemic toxicity (Figure 6). Anti-CD40-BFL treatment resulted in significantly lower serum levels of TNF-α, IL-1β, IL-6, and IFN-γ compared with soluble anti-CD40 mAbs, indicating that the anchoring of anti-CD40 to the liposome could reduce systemic toxicity. The serum levels of TNF-α were 1.56±0.73 ng/L, 40.14±1.91 ng/L, 13.72±2.27 ng/L, 10.14±5.18 ng/L, and 24.3±0.76 ng/L for the physiological saline, anti-CD40 solution, bufalin solution, BFL, and anti-CD40-BFL groups, respectively. Similar trends were observed with IL-1β (2.54±1.07 ng/L, 40.14±1.91 ng/L, 13.89±2.21 ng/L, 16.28±2.76 ng/L, and 14.15±2.53 ng/L, respectively), IL-6 (1.99±0.96 ng/L, 28.07±2.19 ng/L, 6.86±2.64 ng/L, 7.37±1.48 ng/L, and 11.98±2.34 ng/L, respectively) and IFN-γ (13.81±4.92 ng/L, 776.90±37.82 ng/L, 487.23±98.62 ng/L, 332.86±75.95 ng/L, and 534.83±55.14 ng/L, respectively). The serum levels of ALT enzyme (0.709±0.065 mg/mL, 5.872±0.146 mg/mL, 1.613±0.267 mg/mL, 1.808±0.445 mg/mL, and 2.492±0.453 mg/mL, respectively) suggested that the liposome has low toxicity in the liver and that there were no significant safety issues.

**Biodistribution of anti-CD40-BFL**

In order to investigate the biodistribution of anti-CD40-BFL, immunofluorescence histological analysis on cryosections of tumors, spleens, and lymph nodes were performed to directly visualize the local retention of liposomes and anti-CD40. As illustrated in Figure 7, the red fluorescence of liposomes was retained at a high level within the tumor for 24–48 hours postinjection, while anti-CD40 (green) still remained coupled to the liposome (merged for yellow) in vivo. The liposome-anchored anti-CD40 could lead to sustained release and enhanced retention of anti-CD40 in the tumor area, which coincides with the delayed release properties of anti-CD40-BFL in vitro. Meanwhile, the labeled liposomes could be found in spleens and lymph nodes after 48 hours, which implied liposome-induced immunity in both local and systemic immunotherapy. Green fluorescence was barely observed following soluble anti-CD40 therapy after 24 hours, indicating rapid entrance into systemic circulation, which indicates a huge hidden risk of cytokine-release syndrome and short curative effect.

CD40 plays a pivotal role in the immune response via interactions between T cells and antigen-presenting cells. Tumor tissues, spleens, and lymph nodes were harvested 24 hours or 48 hours postinjection and processed into cell suspensions for flow cytometer analysis. Figure 8 illustrates that the amount of DCs (CD11c⁺, CD45⁺), CD4⁺ T cells (CD3⁺, CD4⁺), and CD8⁺ T cells (CD3⁺, CD8a⁺) were positive for anti-CD40-BFL, suggesting the successful delivery of anti-CD40 to its intended targets. After injecting anti-CD40 solution for 24 hours, the quantities of CD4⁺ T cells in tumor tissues, spleens, and lymph nodes were higher than in tissues injected with anti-CD40-BFL, and were mainly distributed in spleens and lymph nodes, and only a few in tumors. Forty-eight hours after injection, the number of CD4⁺ T cells in all tissues was reduced, while...
Figure 5. Apoptosis in control and tumor cells.
Notes: (A) Typical fluorescence microscopic images of TUNEL staining of tumor cytosections treated with saline, free anti-CD40, bufalin, BFL, or anti-CD40-BFL; scale bars denote 100 µm. Blue: cell nuclei, DAPI. Green: apoptosis cells. (B) H&E-stained tumor paraffin sections from mice at the endpoint of the study after treatment with saline, free anti-CD40, bufalin, BFL, or anti-CD40-BFL. Original magnification: 100×. (C) Histogram of mean apoptotic index in each group. (D) Western blot analysis of cytochrome c, caspase-3, and caspase-9 protein in tumor tissues after treatment with saline, free anti-CD40, bufalin, BFL, or anti-CD40-BFL. P-values were determined by paired Student’s t-tests: *P<0.05, **P<0.01 (n=6, mean ± standard error).
Abbreviations: BFL, bufalin liposomes; CYTC, cytochrome c; DAPI, 4,6-diamidino-2-phenylindole; H&E, hematoxylin and eosin; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-fluorescein nick end labeling.
**Figure 6** Serum circulating inflammatory marker levels.

**Notes:** Serum circulating levels 24 hours after the first dose of saline, free anti-CD40, bufalin, BFL, or anti-CD40-BFL. (A) Hepatic enzyme ALT. Inflammatory cytokines (B) TNF-α, (C) IL-6, (D) IL-1β, and (E) IFN-γ. P-values determined by unpaired Student’s t-test: **P<0.01.

**Abbreviations:** ALT, alanine transaminase; BFL, bufalin liposomes; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
the ratio in anti-CD40 solution and anti-CD40-BFL increased. In addition, the fewest CD4+ T cells were found in the bufalin groups, suggesting an immunosuppressive effect. A similar result was found for DCs and CD8+ T cells.

**Discussion**

We have successfully developed an anti-CD40 antibody-mediated bufalin liposome, which was utilized to stimulate apoptosis of B16 melanoma cells, delay growth of tumors, and eliminate systemic side effects (Figure 9). The liposomal delivery vehicle utilized, not only overcame the disadvantages of bufalin, which include poor solubility, immunosuppression, and damage to normal tissue, but also allowed for anti-CD40 to elicit synergistic antitumor effects.

Melanoma, an aggressive skin cancer, represents 4% of all dermatologic cancers yet accounts for more than 80% of all deaths from skin cancer, leaving patients with metastatic melanoma with a 5-year survival rate of <5%.32 Although surgical management remains the primary modality of therapy for patients, it cannot clear tumorigenic or metastatic cells completely and requires supplementation by chemotherapy and/or radiotherapy.33,34 Treatment options for these patients are limited, and no specific immunotherapy vaccine has been approved by the FDA. Dacarbazine or IL-2–based
Figure 8 Bar graph summary of the flow cytometer analysis of excised tumors, spleens, and lymph nodes.

Notes: (A) Percentage of dendritic cells (CD45⁺ CD11c⁺) in tumors, spleens, and lymph nodes after injected saline, free anti-CD40, bufalin, BFL, or anti-CD40-BFL for 24 hours or 48 hours. (B) Percentage of CD4⁺ T cells (CD3⁺ CD4⁺) in tumors, spleens, and lymph nodes after injected saline, free anti-CD40, bufalin, BFL, or anti-CD40-BFL for 24 hours or 48 hours. (C) Percentage of CD8⁺ T cells (CD3⁺ CD8a⁺) in tumors, spleens, and lymph nodes after injected saline, free anti-CD40, bufalin, BFL, or anti-CD40-BFL for 24 hours or 48 hours.

Abbreviation: BFL, bufalin liposomes.
Figure 9 Schematic illustration of immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induce synergetic therapeutic efficacy.

Notes: After anti-CD40-BFL is injected, liposomes enter tumor cells via endocytosis. The bufalin and anti-CD40 are released after liposome fusion. Bufalin induces apoptosis via a caspase-dependent pathway. On the other hand, the anti-CD40 stimulation is delivered by CD40 ligand-expressing activated CD4+ T cells. CD40 ligand binding to CD40 adhesion molecules on the surface of antigen-presenting cells, such as dendritic cells, stimulates the production of cytokines, further induces sufficient cytotoxic T lymphocytes, and produces a systemic immune response.

Abbreviations: BFL, bufalin liposome; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
further induction of sufficient cytotoxic T lymphocytes, and the production of a systemic immune response.

To increase the therapeutic potential of bufalin and anti-CD40, we engineered the lipid membrane bilayer comprising the liposome carriers to overcome certain limitations. The major advantages of liposomal drug delivery are: protection of active compounds from degradation; modification of drug release; an increase in circulation time; and the possibility to achieve partial site. In this study, the three most commonly used preparative methods (thin-film hydration, reverse-phase evaporation, and ethanol injection) were employed to prepare liposomes composed of cholesterol, EPC, DSPE-PEG<sub>2000</sub>, DSPE-PEG<sub>2000</sub>-Mal, and bufalin in a molar ratio of 20:55:5:5:15, respectively. Anti-CD40 was anchored to liposome via a mild maleimide–thiol reaction. This liposome, with a size of 205.4±68.4 nm and a surface property of −15.68 mV, was able to permeate into the tumor microvasculature passively due to the permeable nature of the microvasculature in solid tumors, explained by the EPR effect. Furthermore, quantitative lipid composition of cholesterol within the liposomes was optimized to achieve the desired surface property and drug entrapment (73.59%±3.14%). The cholesterol helped to impart rigidity to the liposome system, but further enhancement above the optimized ratio leads to lipid precipitation and lower drug entrapment. Modification of the surface of nanoparticles with PEG is a successful approach to prolong blood circulation time of nanoparticles, which leads to improved EPR effect-based tumor targeting of encapsulated drugs. Furthermore, the liposome formulation showed sustained release of drug in PBS. A steric protection effect endowed by the antibody chain on the surface of the liposome could minimize the drug’s premature leakage, enabling accumulation of more drugs at the targeted site.

The therapeutic efficacy of anti-CD40-BFL was superior in a B16 melanoma cell mouse xenograft model, which is consistent with the results of cytotoxicity in vitro. The anti-CD40 solution had a minimal inhibitory effect in vitro, which can be explained by the absence of the CD40 receptor on the surface of B16 melanoma cells. An evident anticancer effect was induced by the active systematic immune cytotoxic T lymphocyte, which enhanced antitumor activity and was synergetic with bufalin. In addition, significant changes in body weight and cytokine levels, crucial indicators of systemic side effects, were not observed in the anti-CD40-BFL group compared with mAbs solution alone, which can be attributed to the extended release in the anti-CD40-BFL group and the avoidance of excessive systemic exposure of the liposome. The effect of anti-CD40-BFL was also stronger than bufalin, because of the ability to accumulate in solid tumors due to EPR effect and release of encapsulated bufalin inside the cells via endocytosis of the carrier.

Caspase-3, which is a common effector of most apoptotic pathways, is able to cleave several target proteins whose degradation will contribute to the execution phase of the cell demise program. Cytochrome c was the first mitochondrial protein found to participate in the mitochondria-dependent pathway. In theory, caspase-3 is activated through activation of caspase-9 along with cytosolic release of cytochrome c. Results from our TUNEL and Western blot assays demonstrated apoptosis in visible forms, which is consistent with our aforementioned results.

To generate lifelong immunity against tumor cells, priming of tumor-specific cytotoxic effector cells such as memory T cells is essential. Dendritic cells, one of the representative antigen-presenting cells, can present tumor antigens both on major histocompatibility complex class I and class II proteins for interaction with cytotoxic CD8<sup>+</sup> and CD4<sup>+</sup> T cells. CD40-mediated stimulation of dendritic cells by CD4<sup>+</sup> T cells provides the help required by CD8<sup>+</sup> T cells. CD40 stimulation might be delivered by CD40 ligand-expressing activated CD4<sup>+</sup> T cells, which rapidly express CD40 ligand. Then CD40 ligand binding to CD40 upregulates adhesion/costimulatory molecules on the surface of APCs, such as dendritic cells, which provide the second signal required to activate naïve T cells, amplifying the immune response. Immunofluorescence results indicated the combined mAbs and liposomes could be seen in the tumors, spleens, and lymph nodes after 48 hours, suggesting an extensive systemic immunity effect, as previously suspected. Compared with anti-CD40 solution, anti-CD40-BFL had higher and more enduring fluorescence intensity, which means a slow and sustained release. In addition, the number of DCs, CD8<sup>+</sup> T cells, and CD4<sup>+</sup> T cells were tested by flow cytometry to evaluate their influence on the immune system. Established B16 tumors were injected with PBS, bufalin, anti-CD40 solution, BFL, or anti-CD40-BFL. Tumor tissues, spleens, and lymph nodes were harvested 24 hours or 48 hours postinjection and processed into cell suspensions for analysis. The results indicated that the number of leukocyte cells was higher in anti-CD40 than anti-CD40-BFL groups. These results were reversed 48 hours after injection, due to the sustained-release property of liposomes. A similar change of DCs, CD8<sup>+</sup> T cells, and CD4<sup>+</sup> T cells in tumors, spleens, and lymph nodes implied an active systemic immunity effect.

Future studies will aim to elucidate the optimal proportion of antibody and chemotherapeutics in liposomal delivery.
In addition, distribution of liposome in normal tissue, such as the heart, will be of interest to further investigate the proposed reduced systemic toxicity of bufalin.

Conclusion
Here we reported the formulation and characterization of a liposomal vehicle carrying a combined dose of anti-CD40 and bufalin. This vehicle demonstrated liposome-mediated immune modulation by allowing anti-CD40 to be presented to APCs, which resulted in active potential antitumor effects. Prolonged release at the tumor site while restricting mAbs from entering systemic circulation blocks systemic toxicity. In addition, a synergistic effect of anti-CD40 with bufalin could produce enhanced antitumor responses. The results of this study provide a highly promising strategy for further investigations on other cancer types.

Acknowledgment
This work was financially supported by the National Natural Science Foundation of China (81173513) and the Natural Science Foundation of Shaanxi Province in China.

Disclosure
The authors report no conflicts of interest in this work.

References


Supplementary materials

**Table S1** Characterization of BFL and anti-CD40-BFL

<table>
<thead>
<tr>
<th>Liposome formulation</th>
<th>Particle size (nm), mean ± SD</th>
<th>Polydispersity</th>
<th>Zeta potentials (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BFL</td>
<td>171.4 ± 69.2</td>
<td>0.088</td>
<td>−30.71</td>
</tr>
<tr>
<td>anti-CD40-BFL</td>
<td>205.4 ± 68.4</td>
<td>0.062</td>
<td>−15.68</td>
</tr>
</tbody>
</table>

**Abbreviations:** BFL, bufalin liposomes; SD, standard deviation.

**Table S2** Cytotoxicity of bufalin and liposomal formation against B16 cells (n=6)

<table>
<thead>
<tr>
<th>Bufalin formulation</th>
<th>IC₅₀ (nmol/mL)</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bufalin</td>
<td>224.12</td>
<td>3.14</td>
</tr>
<tr>
<td>BFL</td>
<td>69.91</td>
<td>0.93</td>
</tr>
<tr>
<td>Anti-CD40-BFL</td>
<td>61.73</td>
<td>1.21</td>
</tr>
</tbody>
</table>

**Abbreviations:** BFL, bufalin liposomes; IC₅₀, 50% inhibitive concentration; SD, standard deviation.